Each year, 360-380 patients received blood or marrow transplantation at Stanford BMT program. These include 58% of patients who received high dose chemotherapy followed by autologous hematopoietic cell rescue (Autologous Transplantation). The other 42% of patients had hematopoietic cells from an allogeneic source, such as a HLA-mathced sibling donor, unrelated donors from National Marrow Donor Program, haploidentical donor, or cord blood (Allogeneic Transplantation). A new chimeric antigen receptor (CAR) T-cell program targeting tumor-specific protein has started this year.

We are also a National Marrow Donor Program donation site, and our Cellular Therapy Facility handles over 500 cell products annually.